Cancer Family
Nervous System Neoplasm
CI-CAN-00000038Explore in graph →
Non-malignant1,523 active trials9 approved drugs210 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000038Explore in graph →
Clinical trials
5,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07826949 | A Phase 1 Study of SRN-101 Administered Prior to Surgical Resection in Adults With Recurrent High-Grade Glioma. | not yet recruiting | Phase 1 | 6 | Nicholas ButowskiOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07827001 | PilotStudyAssessSafeActiveSurveillancApproachLocalThe Pa w/BrainMetsUndergoinCNSPenetratSystemicThe | recruiting | — | 12 | University of California, IrvineOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04114981 | Single Fraction Stereotactic Radiosurgery or Three to Five Fraction Stereotactic Radiosurgery in Treating Patients With Brain Metastasis That Has Been Removed by Surgery | active not recruiting | Phase 3 | 242 | Alliance for Clinical Trials in OncologyOTHER | 2 | Sep 17, 2026 | clinicaltrials |
| NCT05421897 | Rapid Administration Pilot for Infusing Dinutuximab(RAPID) | active not recruiting | Phase 2 | 30 | Children's Hospital Los AngelesOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06395103 | Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) | recruiting | Phase 1 / Phase 2 | 90 | Merck Sharp & Dohme LLCINDUSTRY | 23 | Sep 17, 2026 | clinicaltrials |
| NCT06816927 | Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab(GIANT) | recruiting | Phase 2 | 92 | Duke UniversityOTHER | 2 | Sep 17, 2026 | clinicaltrials |
| NCT07376304 | Intraoperative Ultrasound for Brain Tumor Surgery Enhanced by AI(BrainUS-AI) | not yet recruiting | Phase 3 | 100 | Hospital del Rio HortegaOTHER | 0 | Sep 17, 2026 | clinicaltrials |
| NCT07823985 | Preoperative Embolization for Highly Vascular Brain Tumors | not yet recruiting | N/A | 55 | Assiut UniversityOTHER | 0 | Sep 17, 2026 | clinicaltrials |
| NCT01592968 | Stereotactic Radiosurgery or Whole Brain Radiation Therapy in Treating Patients With Newly Diagnosed Non-melanoma Brain Metastases | active not recruiting | Phase 3 | 88 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT02974738 | A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001) | active not recruiting | Phase 1 | 120 | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 0 | Sep 16, 2026 | clinicaltrials |
| NCT03535350 | Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma | active not recruiting | Phase 1 | 36 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04211675 | NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab(STING) | active not recruiting | Phase 1 / Phase 2 | 31 | Nationwide Children's HospitalOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04462328 | Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma | active not recruiting | Phase 1 | 25 | Washington University School of MedicineOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT06630338 | Use of Shear Wave Elastography for Intraoperative Brain and Tumor Stiffness Measurements | not yet recruiting | — | 30 | Mayo ClinicOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07558395 | Effectiveness of a Visual Telerehabilitation Program on Visual Perception in Children, Adolescents and Young Adults With Hemianopsia Consecutive to a Brain Tumour(REVIIH-BT) | not yet recruiting | N/A | 120 | Institut National de la Santé Et de la Recherche Médicale, FranceOTHER_GOV | 7 | Sep 16, 2026 | clinicaltrials |
| NCT02442297 | T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-Positive CNS Tumors(iCAR) | active not recruiting | Phase 1 | 10 | Baylor College of MedicineOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT02974621 | Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma | active not recruiting | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 1 | Sep 15, 2026 | clinicaltrials |
| NCT03115333 | DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma | active not recruiting | N/A | 146 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 15, 2026 | clinicaltrials |
| NCT04065776 | Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma | active not recruiting | N/A | 48 | St. Jude Children's Research HospitalOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT04104529 | Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department(BCB RIV) | recruiting | N/A | 350 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05495295 | First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours(PhAST) | active not recruiting | Phase 1 | 149 | Phost'In TherapeuticsINDUSTRY | 2 | Sep 15, 2026 | clinicaltrials |
| NCT05535166 | Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma | recruiting | Phase 2 | 130 | St. Jude Children's Research HospitalOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05809752 | A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV) | active not recruiting | Phase 1 | 15 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06101069 | Development of MRF for Characterization of Brain Tumors After Radiotherapy | recruiting | N/A | 90 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06132438 | Immunotherapy Targeting of Cytomegalovirus Antigens in Glioblastoma | recruiting | Phase 1 | 26 | Charlotte LemechOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06357377 | A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors | recruiting | Phase 1 | 12 | Neonc Technologies, Inc.INDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07389278 | Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG) | not yet recruiting | Phase 1 / Phase 2 | 97 | Sabine Mueller, MD, PhDOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07655583 | OBSERVE: A Pilot Study Of Omission Of Brain Metastasis Stereotactic Radiosurgery Following Resection With CNS-Active Systemic Therapy | recruiting | Phase 1 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07784985 | A Study of NST-628 in Recurrent Grade 4 Glioma | not yet recruiting | Early Phase 1 | 12 | Nader SanaiOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07819838 | Testing the Addition of an Anti-Cancer Drug, Daraxonrasib, for Relapsed or Refractory Solid Tumors With RAS Mutations | not yet recruiting | Phase 1 / Phase 2 | 77 | Children's Oncology GroupNETWORK | 0 | Sep 15, 2026 | clinicaltrials |
| NCT02704858 | Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma | active not recruiting | Phase 1 / Phase 2 | 49 | Neonc Technologies, Inc.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT02747303 | Frameless Stereotactic Radiosurgery for Intact Brain Metastases | recruiting | Phase 2 | 166 | University of ChicagoOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT03270059 | Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System | recruiting | Phase 2 | 150 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04373720 | MRE Scan for the Assessment of Differences in Tissue Stiffness Between Radiation Necrosis and Recurrent Glioma in Patients With Previously Treated Gliomas | recruiting | N/A | 80 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04771806 | Serial Advanced Magnetic Resonance Imaging Scan for Guidance of Personalized Adaptive Radiotherapy for High Grade Glioma | recruiting | — | 80 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04988009 | Patient Perceptions Around Quality of Care Through Telemedicine in Neuro-Oncology | recruiting | — | 200 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05698524 | A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma | recruiting | Phase 1 | 24 | University of NebraskaOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06674811 | Biomarkers of Resiliency In Childhood Cancer Surgery(BRICCS) | recruiting | — | 40 | Mayo ClinicOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06797661 | Insights Into the Pathophysiology of Neurovascular Uncoupling in Patients With Brain Lesions.(NVUCVR) | recruiting | N/A | 40 | Erasme University HospitalOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07105358 | Vision Improvement Through Behavioral Rehabilitation And Neuroplasticity Training(VIBRANT) | recruiting | N/A | 30 | Georgetown UniversityOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07243470 | Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors(TARLATEM) | recruiting | Phase 1 / Phase 2 | 70 | Centre Leon BerardOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07635329 | Home-based Vision Rehabilitation Guided by Brain Imaging(BRIGHT) | recruiting | N/A | 100 | Georgetown UniversityOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT01199978 | Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma | active not recruiting | Phase 2 | 30 | Massachusetts General HospitalOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT04166409 | A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma | recruiting | Phase 3 | 170 | National Cancer Institute (NCI)NIH | 3 | Sep 11, 2026 | clinicaltrials |
| NCT04870944 | CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma | recruiting | Phase 1 / Phase 2 | 63 | Children's Oncology GroupNETWORK | 2 | Sep 11, 2026 | clinicaltrials |
| NCT04923126 | SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma | recruiting | Phase 1 / Phase 2 | 132 | St. Jude Children's Research HospitalOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07039760 | Asciminib With or Without Sildenafil for Brain Tumors | not yet recruiting | Early Phase 1 | 12 | Washington University School of MedicineOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07061626 | Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade Glioma | recruiting | Phase 1 | 56 | CerenomeINDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07087002 | GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults | recruiting | Phase 1 | 18 | Stanford UniversityOTHER | 1 | Sep 11, 2026 | clinicaltrials |
Data updated 12 days agoSource updated Sep 18, 2026source: clinicaltrials